GlaxoSmithKline PLC banner

GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 2 020 GBX -2.7% Market Closed
Market Cap: £82.1B

GlaxoSmithKline PLC
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

GlaxoSmithKline PLC
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Free Cash Flow
£4.8B
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
22%
AstraZeneca PLC
LSE:AZN
Free Cash Flow
$8.7B
CAGR 3-Years
6%
CAGR 5-Years
32%
CAGR 10-Years
32%
Hikma Pharmaceuticals PLC
LSE:HIK
Free Cash Flow
$119m
CAGR 3-Years
-27%
CAGR 5-Years
-13%
CAGR 10-Years
-6%
Allergy Therapeutics PLC
LSE:AGY
Free Cash Flow
-£36.9m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
-22%
Animalcare Group PLC
LSE:ANCR
Free Cash Flow
£8m
CAGR 3-Years
8%
CAGR 5-Years
-3%
CAGR 10-Years
10%
A
Alliance Pharma PLC
LSE:APH
Free Cash Flow
£37.9m
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
16%
No Stocks Found

GlaxoSmithKline PLC
Glance View

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
1 903.73 GBX
Overvaluation 6%
Intrinsic Value
Price GBX2 020

See Also

What is GlaxoSmithKline PLC's Free Cash Flow?
Free Cash Flow
4.8B GBP

Based on the financial report for Dec 31, 2025, GlaxoSmithKline PLC's Free Cash Flow amounts to 4.8B GBP.

What is GlaxoSmithKline PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
22%

Over the last year, the Free Cash Flow growth was 33%. The average annual Free Cash Flow growth rates for GlaxoSmithKline PLC have been -3% over the past three years , -5% over the past five years , and 22% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett